Bis-isatin hydrazones with novel linkers: Synthesis and biological evaluation as cytotoxic agents. 2016

Hany S Ibrahim, and Sahar M Abou-Seri, and Nasser S M Ismail, and Mahmoud M Elaasser, and Mohamed H Aly, and Hatem A Abdel-Aziz
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt.

Many bis-isatins and isatins with hydrazide extension were reported to have a potential anti-proliferative effects against different cancer cell lines and cancer targets. In this study, four series of bis-isatins with hydrazide linkers were synthesized. These compounds were investigated for their antitumor activity by assessing their cytotoxic potency against HepG2, MCF-7 and HCT-116 cancer cell lines. Compound 21c possessed significant cytotoxic activity against MCF-7 (IC50 = 1.84 μM) and HCT-116 (IC50 = 3.31 μM) that surpasses the activity of doxorubicin against both cell lines (MCF-7; IC50 = 2.57 μM and HCT-116; IC50 = 3.70 μM). Cell cycle analysis and annexin V-FITC staining of MCF-7 cells treated with 21c suggested that the cytotoxic effect of the compound could be attributed to its pro-apoptotic activity.

UI MeSH Term Description Entries
D007510 Isatin An indole-dione that is obtained by oxidation of indigo blue. It is a MONOAMINE OXIDASE INHIBITOR and high levels have been found in urine of PARKINSONISM patients. 2,3-Dioxoindoline,2,3 Dioxoindoline
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D003603 Cytotoxins Substances that are toxic to cells; they may be involved in immunity or may be contained in venoms. These are distinguished from CYTOSTATIC AGENTS in degree of effect. Some of them are used as CYTOTOXIC ANTIBIOTICS. The mechanism of action of many of these are as ALKYLATING AGENTS or MITOSIS MODULATORS. Cytolysins,Cytotoxic Agent,Cytotoxic Agents,Cytotoxin,Agent, Cytotoxic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006835 Hydrazones Compounds of the general formula R:N.NR2, as resulting from the action of hydrazines with aldehydes or ketones. (Grant & Hackh's Chemical Dictionary, 5th ed) Hydrazone
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Hany S Ibrahim, and Sahar M Abou-Seri, and Nasser S M Ismail, and Mahmoud M Elaasser, and Mohamed H Aly, and Hatem A Abdel-Aziz
January 2012, Bioorganic & medicinal chemistry letters,
Hany S Ibrahim, and Sahar M Abou-Seri, and Nasser S M Ismail, and Mahmoud M Elaasser, and Mohamed H Aly, and Hatem A Abdel-Aziz
January 2024, Bioorganic & medicinal chemistry letters,
Hany S Ibrahim, and Sahar M Abou-Seri, and Nasser S M Ismail, and Mahmoud M Elaasser, and Mohamed H Aly, and Hatem A Abdel-Aziz
April 2015, International journal of molecular sciences,
Hany S Ibrahim, and Sahar M Abou-Seri, and Nasser S M Ismail, and Mahmoud M Elaasser, and Mohamed H Aly, and Hatem A Abdel-Aziz
July 2020, Advanced pharmaceutical bulletin,
Hany S Ibrahim, and Sahar M Abou-Seri, and Nasser S M Ismail, and Mahmoud M Elaasser, and Mohamed H Aly, and Hatem A Abdel-Aziz
January 2019, Medicinal chemistry (Shariqah (United Arab Emirates)),
Hany S Ibrahim, and Sahar M Abou-Seri, and Nasser S M Ismail, and Mahmoud M Elaasser, and Mohamed H Aly, and Hatem A Abdel-Aziz
May 2013, Archives of pharmacal research,
Hany S Ibrahim, and Sahar M Abou-Seri, and Nasser S M Ismail, and Mahmoud M Elaasser, and Mohamed H Aly, and Hatem A Abdel-Aziz
November 2016, Molecules (Basel, Switzerland),
Hany S Ibrahim, and Sahar M Abou-Seri, and Nasser S M Ismail, and Mahmoud M Elaasser, and Mohamed H Aly, and Hatem A Abdel-Aziz
April 2013, Drug research,
Hany S Ibrahim, and Sahar M Abou-Seri, and Nasser S M Ismail, and Mahmoud M Elaasser, and Mohamed H Aly, and Hatem A Abdel-Aziz
August 2004, Bioorganic & medicinal chemistry,
Hany S Ibrahim, and Sahar M Abou-Seri, and Nasser S M Ismail, and Mahmoud M Elaasser, and Mohamed H Aly, and Hatem A Abdel-Aziz
May 2009, Expert opinion on investigational drugs,
Copied contents to your clipboard!